PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.

Slides:



Advertisements
Similar presentations
Caribbean Central American Action (CCAA) Strengthening in the Third Border (CBI) CCA 27 th Annual Miami Conference on the Caribbean Basin Dr Rosanna Cooper,
Advertisements

Intellectual property rights and procurement = international developments & national experiences = Bi-regional Workshop on procurement and supply management.
Differential pricing and access to medicines: issues and options Andrew Creese Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals.
1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.
Options for national or regional production or procurement Wilbert Bannenberg SARPAM.
Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.
The Emergence of Anti-Counterfeiting Legislation in East Africa: Implications for Generic Supply and Treatment Access Mandeep Dhaliwal Tenu Avafia With.
Access to medicines – Barriers relating to intellectual property rights and data exclusivity Julian Cockbain & Sigrid Sterckx Yale conference Human rights.
Possible Impact of Market Exclusivity Extension on Pharmaceuticals in Thailand Chutima Akaleephan International Health Policy Program, Thailand 27 August.
“Using Competition Law to Promote Access to Health Technologies” Access to Innovation: Making Generic Versions of Newer ARVs Affordable 24 July 2014 Melbourne,
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Challenges and Opportunities to Utilize TRIPS Flexibilities in Current Ukrainian Legislation: Potential Impact of IP Provisions in the Proposed EU FTA.
Greedy Sleazy Patent Owners vs. Poor Sick People International Patent Protection and Access to Drugs in the Third World Liz Durham November 4, 2003.
Intellectual Property Rights, Services and Trade Facilitation CARSTEN FINK African/LDCs Ambassadors Seminar on Post-Hong Kong Assessment of the Doha Round,
The use of TRIPS flexibilities to protect health in South Africa and the opportunities for pro-public health reform of national legislation Nokhwezi Hoboyi.
Presentation to Civil Society meeting Lusaka 1 October 2013.
IP News 指導老師:李柏靜 學生:黃馨葦 M /3/26.  Citing the high cost of one of the pharmaceutical industry's expensive new cancer drugs, India's patent.
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
1 Intellectual Property Rights in Medicines Procurement Patrick Osewe Senior HIV/AIDS Specialist World Bank.
A very short introduction to patents & access to medicines.
Medicines & Related Substances Amendment Bill: Protecting the Nation’s Health “The State must take reasonable legislative and other measures, within its.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA AN OVERVIEW OF PATENT PROTECTION IN ZAMBIA.
Patent Related Flexibilities in the Pharmaceutical Field
Access to Essential Medicines and Intellectual Property Rights in Developing Countries Rachel M. Cohen Access to Essential Medicines Campaign Doctors Without.
Public health, innovation and intellectual property 1 |1 | Dr Germán Velásquez Director WHO Secretariat Public Health, Innovation and Intellectual Property.
Procurement of patented and other essential medicines: challenges and opportunities Wilbert Bannenberg, MD MPH Zambia TRIPS workshop.
TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.
Patents, TRIPS, Flexibilities & Access to Medicines –Legal Perspective Lesotho Civil Society Consultation Meeting 12 August 2014.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
 .
Intellectual Property Rights and Access to Medicines: an Overview and Introduction to the TRIPS flexibilities Workshop on the Utilization of the TRIPS.
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
LESOTHO VALIDATION WORKSHOP 25 NOVEMBER 2014 CAILIN MORRISON RECAP – THE INTERNATIONAL CONTEXT: THE WTO, PATENTS, TRIPS FLEXIBILITIES & ACCESS TO MEDICINES.
Patents, access to medicines and the WTO ’ s TRIPs Agreement Consultative meeting on incorporation of TRIPs Flexibilities Morogoro, Tanzania 24 July 2006.
WHO Perspective on Medicine Patents and FTAs Asian Regional Workshop on FTAs August, 2005, Kuala Lumpur, Malaysia Dr Zafar Mirza Regional Adviser,
1 CUTS International Capacity Building Training Programme on Advance IPR, WTO-Related Issues and Patent Writing April 28-May 02, 2008, Jaipur Session 10.
Options for national/regional production of generic medicines Wilbert Bannenberg, MD MPH Lesotho TRIPS workshop 14 Aug 2014.
Zimbabwe CSOs TRIPS and Access to medicines Aulline Mabika-Chapisa.
Ten Years of the Doha Declaration: The State of Implementation Geneva 14 November
Ideas in Development The Potential Impact of WTO Accession, FTAs and Partnership & Cooperation Agreements (PCAs) on Access to Medicines.
Getting the best treatment to the most people possible Enabling policies: threats & opportunities MSF Access Campaign.
MFJ International, LLC A Global Consulting Firm “FTAs and Pharmaceuticals: a hijacked process?” M. Fabiana Jorge CPTECH November 16, 2006.
Page 1 Implementation of the WTO Decision on TRIPS and Public Health Government of Canada August 2004.
Do Patents Make HIV/AIDS Medication Inaccessible to Patients in Sub-Saharan Africa? Abstract There has been debate surrounding the issue of patents and.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
O VERVIEW OF P UBLIC H EALTH -R ELATED TRIPS F LEXIBILITIES Sisule F. Musungu, IQsensato (
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
UNCTAD/CD-TFT 1 IP Provisions in Bilateral & Regional Trade Agreements and Public Health ICTSD/QUNO Dinner Discussion on IPRs in Bilateral & Regional Trade.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
A: Copy –Rights – Artistic, Literary work, Computer software Etc. B: Related Rights – Performers, Phonogram Producers, Broadcasters etc. C: Industrial.
Presentation to Civil Society meeting Harare 21 January 2014.
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.
‘Linkage’ & other TRIPS+ provisions: a public health perspective Karin Timmermans World Health Organization Seminar “Data exclusivity and patent Bangkok.
A presentation by Moses Nkomo Intellectual Property Attorney and Consultant National Workshop on TRIPS and access to medicines in Zimbabwe Holiday Inn,
Implementation of TRIPS Flexibilities In National IP Legislation For Strengthening Access To Medicines In Swaziland Workshop with MOH and stakeholders,
South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.
Access to medicines Elizabeth Holzer, Legal Policy Advisor A global and local - legal and health systems issues.
Introduction: Intellectual Property Rights and its impact on access to medicines Anand Grover United Nations Special Rapporteur on Health East Africa Consultation,
TRIPS-Plus Pressures: Trade Agreements, and New Trade Policy Prof. Brook K. Baker OSI Kiev – IPRs & A2M, Sept. 16, 2009.
FREE TRADE AGREEMENTS Prathibha Siva Lawyers Collective HIV/AIDS Unit, India East Africa Consultation, September 2010.
NAFTA, CAFTA and Access to Medicines and Food Security in Latin America International Aids Conference Session “Globalization and FTAs: their impact, access.
1 Special mechanism for the importation of pharmaceutical products under the TRIPS Agreement Carlos M. Correa.
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
WTO and medicines: from Doha to Cancún
Intellectual Property Protection and Access to Medicines
PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES
Acceptance of the Protocol Amending the TRIPS Agreement
Intellectual Property Rights in Medicines Procurement
Presentation transcript:

PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG. OFF. RESEARCH & MONITORING (HEALTH & HUMAN RIGHTS). HEPS – UGANDA.

WHAT IS A PATENT? Is an exclusive right awarded to an inventor to prevent others from making, selling, distributing, importing or using their invention, without license or authorisation from the patent holder for a fixed period of time (TRIPS Agreement stipulates at least 20 years of protection).

WHAT IS HEALTH? “Health is a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity.” (1946 WHO CONST’N)

REQUIREMENTS FOR PATENTABILITY OF AN INVENTION 1.Novelty- New characteristics which are not “prior art”. 2.An Inventive Step – Not obvious to one skilled in the field. 3.Industrial Applicability.

WHAT IS THE IMPLICATION OF PATENTS ON HEALTH? 1.Patent Rights on Medicines lead to Monopoly Pricing, Affordable only to the Rich. E.G, a 20 year Patent for an Essential Medicine will mean that only the Patent holder can produce it for that period, before Competitors can be permitted to produce it. And during the 20 years, the Patent holder can most likely produce less than the required quantities and sell at high prices.

IMPLICATION OF PATENTS ON HEALTH CONTINUED The above can mean that many people, particularly in poor countries like Uganda, would die due to inability to afford the Medicine. This can be worse in the case of dynamic diseases like HIV/AIDS, where new Medicines are being continuously developed to keep pace with the changing nature of the HIV virus. Long Patents for such Medicines may deny poor people access forever!

IMPLICATION OF PATENT ON HEALTH CONTINUED 2. A Patent gives the holder the Right to exclude Competition. 3. Right to set prices at what the Market will bear. E.G, “Research Based” Pharmaceutical Companies (Basically Multinational Cos) use the protection & enforcement of Patents & Test Data to gain monopoly rights which then allows them to charge very high prices & obtain profitability.

IMPLICATION OF PATENT ON HEALTH CONTINUED E.G, in 2000, the price of HAART in Kampala & Durban S.A was the same as in NY City- $ 10,439 per patient per year. However, today due to the entry of Generic Drugs from India that had no Patent protection for Pharmaceutical products & thus was able to manufacture Generic versions of patented products; prices have reduced dramatically to less than 150$ per person per year- 6.6 Million people in low-income countries now have access to ARVs.

CHALLENGE TO HEALTH BY OTHER UGANDAN IPR PROPOSED LEGISLATION INDUSTRIAL PROPERTY BILL,2009; Doesn’t provide for any extension period; Bolar provisions only allow Scientific Research; it excludes Drug Testing, approval & registration which may delay post-patent competition; on Compulsory license, unnecessary barriers have been proposed by requiring applicants to go through lengthy court procedures. ANTI-COUNTERFEIT GOODS BILL NO.22 /2012; Risk of wrongful Border seizures still high. Both Bills still have TRIPS-Plus provisions; Industrial Property Bill has not fully utilised TRIPS Flexibilities that protect & promote public health particularly access to medicines.

CONCLUSION In designing Intellectual Property Laws that affect Public Health for example Patents, there is need to retain maximum Policy space for Generic competition by utilising the Flexibilities / safeguards provided by the TRIPS Agreement. It is worth recalling the WTO’s Doha Declaration on the TRIPS Agreement & Public Health that confirm the right of WTO Members to implement the TRIPS obligations in a manner that ensures the protection of Public Health particularly Access to Medicines by all. We call upon all LDCs to support the push for a Transition Period to either 2025 OR 2030 to be TRIPS compliant; our technology & Pharmaceutical Industry is still wanting; E.G, 90% of Uganda’s Medicines are imports from India; we have only one Pharmaceutical Industry (QCIL) manufacturing ARVs of a Generic Version.

THANK YOU FOR LISTENING, PLIZ!!!